Home/Recalls/FDA-D-0657-2026
FDA DrugsClass II

Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release ...

Published: July 8, 2026Recall ID: D-0657-2026Category: drugsCountry: US

Reason for Recall / Hazard

CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.

Product Description & Identification

Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets), 12.5/1000 mg, 60 Tablets per Bottle, Rx only, Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877 USA. NDC: 00597-0300-45

Affected Products

Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets), 12.5/1000 mg, 60 Tablets per Bottle, Rx only, Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877 USA. NDC: 00597-0300-45

Additional Source Details

FieldValue
CityRidgefield
StateCT
Event id99233
Address 1900 Ridgebury Rd
Address 2N/A
Code infoLot 3244413; Exp. 12/31/2028
Postal code06877-1058
Report date20260708
Product typeDrugs
Product quantity560 bottles
Reason for recallCGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.
Voluntary mandatedVoluntary: Firm initiated
Recall initiation date20260612
Initial firm notificationLetter
Center classification date20260630

Overview

  • Recalling FirmBoehringer Ingelheim Pharmaceuticals, Inc.
  • StatusOngoing
  • Risk LevelClass II
  • DistributionOH
Official Agency Alert